433 related articles for article (PubMed ID: 30798356)
1. T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances.
Yu L; Wang J
J Cancer Res Clin Oncol; 2019 Apr; 145(4):941-956. PubMed ID: 30798356
[TBL] [Abstract][Full Text] [Related]
2. Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.
Strohl WR; Naso M
Antibodies (Basel); 2019 Jul; 8(3):. PubMed ID: 31544847
[TBL] [Abstract][Full Text] [Related]
3. Activated T cells armed with bispecific antibodies kill tumor targets.
Bhutani D; Lum LG
Curr Opin Hematol; 2015 Nov; 22(6):476-83. PubMed ID: 26457960
[TBL] [Abstract][Full Text] [Related]
4. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.
Satta A; Mezzanzanica D; Turatti F; Canevari S; Figini M
Future Oncol; 2013 Apr; 9(4):527-39. PubMed ID: 23560375
[TBL] [Abstract][Full Text] [Related]
5. Targeting T cells with bispecific antibodies for cancer therapy.
Lum LG; Thakur A
BioDrugs; 2011 Dec; 25(6):365-79. PubMed ID: 22050339
[TBL] [Abstract][Full Text] [Related]
6. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Antibody Armed T Cells to Target Cancer Cells.
Thakur A; Lum LG; Mittal S
Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
Suzuki M; Curran KJ; Cheung NK
Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
[TBL] [Abstract][Full Text] [Related]
9. Recent advances of bispecific antibodies in solid tumors.
Yu S; Li A; Liu Q; Yuan X; Xu H; Jiao D; Pestell RG; Han X; Wu K
J Hematol Oncol; 2017 Sep; 10(1):155. PubMed ID: 28931402
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
Kipriyanov SM; Le Gall F
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
[TBL] [Abstract][Full Text] [Related]
11. Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.
Yuraszeck T; Kasichayanula S; Benjamin JE
Clin Pharmacol Ther; 2017 May; 101(5):634-645. PubMed ID: 28182247
[TBL] [Abstract][Full Text] [Related]
12. "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.
Thakur A; Lum LG
Expert Opin Biol Ther; 2016; 16(5):675-88. PubMed ID: 26848610
[TBL] [Abstract][Full Text] [Related]
13. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
14. Engineering Immune Cells for
Blanco B; Ramírez-Fernández Á; Alvarez-Vallina L
Front Immunol; 2020; 11():1792. PubMed ID: 32903593
[TBL] [Abstract][Full Text] [Related]
15. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
16. Using antibodies in tumour immunotherapy.
Schultes BC; Nicodemus CF
Expert Opin Biol Ther; 2004 Aug; 4(8):1265-84. PubMed ID: 15268661
[TBL] [Abstract][Full Text] [Related]
17. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
18. T Cell-Redirecting Strategies to 'STAb' Tumors: Beyond CARs and Bispecific Antibodies.
Blanco B; Compte M; Lykkemark S; Sanz L; Alvarez-Vallina L
Trends Immunol; 2019 Mar; 40(3):243-257. PubMed ID: 30827461
[TBL] [Abstract][Full Text] [Related]
19. Advances in bispecific biotherapeutics for the treatment of cancer.
May C; Sapra P; Gerber HP
Biochem Pharmacol; 2012 Nov; 84(9):1105-12. PubMed ID: 22858161
[TBL] [Abstract][Full Text] [Related]
20. Targeting T cells to tumor cells using bispecific antibodies.
Frankel SR; Baeuerle PA
Curr Opin Chem Biol; 2013 Jun; 17(3):385-92. PubMed ID: 23623807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
